Breakdown of This Biotech Massacre
Shares of Aeterna Zentaris were gutted on the market Monday, down 25% intraday. In this video, Motley Fool health-care analyst David Williamson takes a look at a horrendous 12-month period for the company overall, and how hanging its hopes on its drug Perifosine has resulted in disappointment after disappointment in clinical trials.
While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.
The article Breakdown of This Biotech Massacre originally appeared on Fool.com.David Williamson has no position in any stocks mentioned. The Motley Fool owns shares of Dendreon. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.